Vaccine Process Development and CMC Readiness

This contract focuses on the development and optimization of scalable manufacturing processes for vaccine candidates, encompassing key stages such as cell culture or egg-based production, purification, formulation, and stability testing. The goal is to ensure that vaccine manufacturing processes are efficient, reproducible, and meet quality standards necessary for further clinical and commercial development. The work is critical to advancing vaccine candidates through Chemistry, Manufacturing, and Controls (CMC) readiness. Issued by the Department of Health and Human Services through BARDA, the subcontract opportunity is set in Washington, D.C., with a solicitation posted on June 3, 2026. Interested parties need to respond by July 15, 2026. The contract falls under the NAICS code 325412, which pertains to pharmaceutical preparation manufacturing. This opportunity supports the public health mission to accelerate vaccine availability by enhancing manufacturing capabilities.